to contribute to well-being of humanity by treating chronic immune diseases through peptide drugs we discover and develop.
Thank you for visiting our website.
KINE SCIENCES is a company that develops ultra-small peptide innovative medicines based on functional immunomics.
We discovered the function of a novel cytokine ERDR1 for the first time in the world and since we have been developing drug candidates of ultra-small peptide with private and public funding including the one from Korea Drug Development Fund for consecutive four years.
The diseases we aim to treat are chronic immune diseases such as rheumatoid arthritis, inflammatory bowel diseases, atopic dermatitis, psoriasis, cancer, Alzheimer’s disease, and many rare immune diseases.
Though we live in an era when we see more research on life sciences and more drugs on the market than any other era of human history, we humans have yet to find cures for these chronic immune diseases by seeing occurrence of resistance or relapse which make lifelong treatment of expensive medicines inevitable for patients.
These diseases put a great burden not only on patients themselves but their families and the society as a whole.
KINE SCIENCES is committed to treating chronic immune diseases, making lives of patients and their families better, and ultimately improving well-being of humanity by developing safer, more economical and more convenient medicines of ultra small peptides.
Please give us encouragement and support for our daunting journey.
CTO Dae Ho Cho
Ph.D., Chicago Medical School; B.S., SUNY
Professor of Convergence Research Institute, Korea University
Head of Nano Bio Material Research Center, Korea University
Professor of Department of Life Sciences, Sookmyung Women's University
Sa Ik Bang M.D, Ph.D
B.S., M.S., & Ph.D, Seoul National University, College of Medicine
Professor of Medical School, Sungkyunkwan University
Head of External Cooperation Office, Samsung Medical Center
Head of Strategic Planning Office, Samsung Medical Center
MBA, Sogang University; B.S. Pharmacy, Seoul National University
SVP, Clinical Science Division & RA, Samsung Bioepis
VP, Strategic Business Development, Samsung Electronics
Head of Market Access Division & Compliance, Novartis Korea
B.A. Business Administration, Korea University
CFO and COO of Hanel
CFO of Meere Company
CPA of Samil PwC
MBA, Korea University
Vice President, Strategic Planning & BD, NKMAX
General Manager, M&A Team, Samsung Fire & Marine
Project Manger, A.T Kearney/Deloitte
M.S. Virolgy & Immunolgy, Ulsan University
Chief Researcher, Central Research Institutes, IL-YANG Pharmaceuticals
Team Leader, SIS Immunology Research Center, Sookmyung Women's University
Ph.D., Cell Biology, Sookmyung Women's University
Senior Researcher, Sookmyung Women's University
Senior Researcher, SIS Immunology Research Center, Sookmyung Women's University
Research Professor, Sookmyung Women’s University
Ph.D., College of Medicine, Seoul National University; B.S. Biological Sciences, KAIST
Chief Researcher, Strategic Business Development Lead, CHABiotech
Principal Engineer, Corporate Management and Business Development, Samsung Bioepis
Senior Engineer, Samsung Advanced Institute of Technology, Samsung Electronics